Key Laboratory of Cardiovascular and Cerebrovascular Medicine, Nanjing Medical University, Nanjing, 201203, China.
Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, 201203, China.
Acta Pharmacol Sin. 2022 Mar;43(3):602-612. doi: 10.1038/s41401-021-00674-9. Epub 2021 May 19.
Cardiac fibrosis (CF) is an irreversible pathological process that occurs in almost all kinds of cardiovascular diseases. Phosphorylation-dependent activation of c-Jun N-terminal kinase (JNK) induces cardiac fibrosis. However, whether S-nitrosylation of JNK mediates cardiac fibrosis remains an open question. A biotin-switch assay confirmed that S-nitrosylation of JNK (SNO-JNK) increased significantly in the heart tissues of hypertrophic patients, transverse aortic constriction (TAC) mice, spontaneously hypertensive rats (SHRs), and neonatal rat cardiac fibroblasts (NRCFs) stimulated with angiotensin II (Ang II). Site to site substitution of alanine for cysteine in JNK was applied to determine the S-nitrosylated site. S-Nitrosylation occurred at both Cys116 and Cys163 and substitution of alanine for cysteine 116 and cysteine 163 (C116/163A) inhibited Ang II-induced myofibroblast transformation. We further confirmed that the source of S-nitrosylation was inducible nitric oxide synthase (iNOS). 1400 W, an inhibitor of iNOS, abrogated the profibrotic effects of Ang II in NRCFs. Mechanistically, SNO-JNK facilitated the nuclear translocation of JNK, increased the phosphorylation of c-Jun, and induced the transcriptional activity of AP-1 as determined by chromatin immunoprecipitation and EMSA. Finally, WT and iNOS mice were subjected to TAC and iNOS knockout reduced SNO-JNK and alleviated cardiac fibrosis. Our findings demonstrate an alternative mechanism by which iNOS-induced SNO-JNK increases JNK pathway activity and accelerates cardiac fibrosis. Targeting SNO-JNK might be a novel therapeutic strategy against cardiac fibrosis.
心肌纤维化(CF)是几乎所有心血管疾病都发生的一种不可逆的病理过程。依赖磷酸化的 c-Jun N-末端激酶(JNK)的激活诱导心肌纤维化。然而,JNK 的 S-亚硝基化是否介导心肌纤维化仍然是一个悬而未决的问题。生物素转换测定法证实,肥厚患者、腹主动脉缩窄(TAC)小鼠、自发性高血压大鼠(SHR)和血管紧张素 II(Ang II)刺激的新生大鼠心肌成纤维细胞(NRCFs)中的 JNK 的 S-亚硝基化(SNO-JNK)显著增加。应用 JNK 中的半胱氨酸取代丙氨酸的位点到位点取代来确定 S-亚硝基化位点。S-亚硝基化发生在 Cys116 和 Cys163 处,并且半胱氨酸 116 和半胱氨酸 163(C116/163A)的丙氨酸取代抑制了 Ang II 诱导的肌成纤维细胞转化。我们进一步证实,S-亚硝基化的来源是诱导型一氧化氮合酶(iNOS)。iNOS 的抑制剂 1400W 消除了 Ang II 在 NRCFs 中的促纤维化作用。从机制上讲,SNO-JNK 促进了 JNK 的核易位,增加了 c-Jun 的磷酸化,并通过染色质免疫沉淀和 EMSA 确定了 AP-1 的转录活性。最后,WT 和 iNOS 小鼠进行 TAC 实验,iNOS 敲除减少了 SNO-JNK 并减轻了心肌纤维化。我们的研究结果表明,iNOS 诱导的 SNO-JNK 增加 JNK 途径活性并加速心肌纤维化的另一种机制。靶向 SNO-JNK 可能是一种针对心肌纤维化的新型治疗策略。